Top Stories
The anti–PD-L1 mAb was approved an adjuvant treatment in combination with oxaliplatin and a fluoropyrimidine chemotherapy for mismatch repair deficient (dMMR) Stage III disease.
At the midpoint of its proposed offering, Iambic would raise $150 million.
The deal will add Pacira's marketed products Exparel and Zilretta to Viatris' portfolio.
Zenbexus (iberdomide), a cereblon E3 ligase modulator (CELMoD), gained accelerated FDA approval in August to treat adults with MM who have received at least one prior line of therapy.
FB102 is moving into Phase III testing after hitting the main goal of a mid-stage coeliac study.
Conference News
SAN DIEGO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science...
ZUG, Switzerland and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310®, its investigational CRISPR/Cas9...
Three scientific presentations will highlight new analyses of VOQUEZNA® (vonoprazan) in GERD, including real-world patient characteristics, efficacy across BMI subgroups, and cost-effectiveness in Ero...
VANCOUVER, Washington, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized mon...
TEL AVIV, Israel, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that an additional present...
